Rapport TherapeuticsRAPP -0.60%14 PB Ratio is 4.24 as of Jul. 10, 2026, which is 11% above its 10-year median of 3.82. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 1,227 Biotechnology companies, Rapport Therapeutics ranks worse than 63.81% on this metric.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Rapport Therapeutics PB Ratio Related Terms
Rapport Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Rapport Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rapport Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapport Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Rapport Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Rapport Therapeutics (RAPP) has a PB Ratio of 4.24 as of Jul. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rapport Therapeutics and its competitors. This is 11% above median its historical median of 3.82. Over the past decade, Rapport Therapeutics' PB Ratio has ranged from 3.40 to 4.27. According to the industry distribution chart, Rapport Therapeutics ranks #783 out of 1227 companies in the Biotechnology industry, placing it in the top 63.8%.
Is Rapport Therapeutics' PB Ratio too high?
Rapport Therapeutics' current PB Ratio of 4.24 is 11% above median its 10-year median of 3.82. Over the past 10 years, this metric has ranged from a low of 3.40 to a high of 4.27. The Biotechnology industry median PB Ratio is 2.95. Rapport Therapeutics' value of 4.24 is 43.7% above this industry median. Based on the distribution chart, Rapport Therapeutics ranks #783 out of 1227 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' PB Ratio compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #783 out of 1227 companies for PB Ratio. This places Rapport Therapeutics in the lower half of its industry. The industry median PB Ratio is 2.95. Rapport Therapeutics' value of 4.24 is 43.7% above this benchmark. Historically, Rapport Therapeutics' own PB Ratio has ranged from 3.40 to 4.27 over the past decade. While the company's 10-year median is 3.82 vs. the industry median of 2.95, Rapport Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapport Therapeutics's current PB Ratio of 4.24 is 43.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Rapport Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapport Therapeutics's current PB Ratio is 4.24, which is 11% above median its own 10-year median of 3.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current PB Ratio of 4.24. The current PB Ratio is 4.24, which is 11% above median its 10-year median of 3.82 and 43.7% above the Biotechnology industry median of 2.95. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current PB Ratio is 4.24 as of Jul. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score
Get the complete analysis for RAPP
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RAPP has been successfully added to your 
